Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Oncotherapy Plc LSE:AVO London Ordinary Share GB00BD6SX109 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 36.00 76,668 13:03:09
Bid Price Offer Price High Price Low Price Open Price
35.00 37.00 36.00 35.50 36.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services -25.30 -8.75 163
Last Trade Time Trade Type Trade Size Trade Price Currency
13:05:09 O 13,741 36.30 GBX

Advanced Oncotherapy (AVO) Latest News

More Advanced Oncotherapy News
Advanced Oncotherapy Investors    Advanced Oncotherapy Takeover Rumours

Advanced Oncotherapy (AVO) Discussions and Chat

Advanced Oncotherapy (AVO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Advanced Oncotherapy trades in real-time

Advanced Oncotherapy (AVO) Top Chat Posts

Advanced Oncotherapy Daily Update: Advanced Oncotherapy Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker AVO. The last closing price for Advanced Oncotherapy was 36p.
Advanced Oncotherapy Plc has a 4 week average price of 33.50p and a 12 week average price of 33.50p.
The 1 year high share price is 45p while the 1 year low share price is currently 32p.
There are currently 452,112,211 shares in issue and the average daily traded volume is 54,100 shares. The market capitalisation of Advanced Oncotherapy Plc is £162,760,395.96.
altom: I cannot remember any other placing well above mkt price, like AVO. This must be positive news imho. I expect things to be very different by Easter. I am LTH and have been v.disappointed before, but surely this time……………
gerhart: Daijavu, I agree that with AVO it has seemed like the long and winding road, rinse and repeat. As I said before the letters of intent are meaningless. If the tech works, they can be sure there will be lots of orders. And if it doesn't, then there won't be any. Though I guess we have to cut the company some slack for the covid period of disruption. Whether that will cause knock on problems now due to NHS (and other countries) being way behind on ordinary work, or it will provide opportunities due to terrible tragic delay in cancer treatment for patients, we will see. I guess from the latest placing, we could be positive and ask ourselves why investors were prepared to pay well above market price. Are they so confident on what is coming relatively soon, obviously based on what they have been shown/told?
daijavu: I'm waiting for solid news about progress with LIGHT. Nothing else matters. The rest is dilution, cash burn and ify news about possible contracts that might disappear into the ether like all the other AVO contracts before them.
uncleoswald: The last post was correct..... They did need a large injection of cash. But to raise it at a price above the current share price is surprising and unusual, but very good for the share price!!
daijavu: Hi Twirl and robbiekeane I was a LTH of AVO until I realised just how unreliable and untrustworthy the BoD are. I sold at 50p about 3 years ago. I'm now invested in a swathe companies, most of which are doing well. The two things that keep me interested in AVOare LIGHT itself and the fact that the original main shareholders have never sold. It is not impossible that we might see a repeat of 2018, with LIGHT not operational this year and the BoD issuing a revised development schedule early next year. Apart from that I agree that AVO probably needs a big injection of capital to manufacture and sell LIGHT in sufficient quantities to make the sort of profits we want to see.
daijavu: robbiekeane I don't know how long you've been an AVO watcher. If it's been as long as I have you would know that this is not new news. AVO has been here before. Several times. It came to nothing each time. I'm not saying that LIGHT will never work but I have had enough experience of the AVO BoD to want to see the money before I put any more of mine in. It might be later this year or it might be next year or it might be in five or ten years time. What is certain is that we are not there yet and I am not going to take any notice of yet another LOI or yet another of the many contracts that AVO have had and failed to meet. You are welcome to put your money in, if that is your choice.
robbiekeane: Broker note (house)... AVO Advancing to Sales Advanced Oncotherapy (LSE: AVO) After six- seven years and over £130m investment in intense technical development the next generation of proton beam therapy (PBT) machine, today AVO took a significant commercial step forward. As it is announced that AVO have signed an LOI (Letter of Intent) with Saba Partners to purchase a three- treatment room LIGHT system for around £75.5m. The system is to be installed at Glion in Switzerland which has been acquired by Saba Partners who are building a medical centre of excellence there. This is subject to a CE mark which is should be a mere formality and well on track for the LOI to become binding by March 2022. Proton Beam is a well-established cancer treatment which until now has been rationed by the prohibitive costs. AVO’s technology, inspired by Cern of Geneva, significantly reduces the costs of this life saving treatment and there is significant potential market for the LIGHT system where it is estimated that 4,000 proton therapy centres are required worldwide to meet the demand while only 95 facilities currently exist. Working with Saba Partners over time there is the potential make the LIGHT system available to countries within the Gulf region. Other such deals seem likely and as the technical milestones are passed the higher AVO’s value becomes, This prospect is not reflected in the price at 38p and a market cap of £129m. Buy for the medium term.
daijavu: Hi twirl. I didn't realise you were still around. Nothing much seems to have changed with AVO since the old days we lived through with them back around 2016. Where did all those contracts and all that cash disappear to? Today they've announced yet another contract. Subject to them ever getting LIGHT to work, of course. We both have painful memories of the rock solid promises that they were absolutely, definitely, undeniably, on track to have LIGHT up and running by the end of that year. Then, when they eventually admitted that they were still years away from completion, all those Chinese contracts vanished, the share price tanked and Sinophi demanded their money back. I barely got out with my shirt. How much did you lose?
robbiekeane: There is a Goetz Partners research note 27/04/2021 on AVO (paid for by Co.) stating Outperformance and a target price of £1.35. It's a detailed piece of work (17 pages). The summary: Our Discounted Cash Flow (DCF) analysis for AVO is shown in CHART 14. We have chosen to value the company on a DCF basis for a number of reasons. Firstly, AVO is a relatively young company in terms of its commercialisation stage in PT and while the technology is older than sixty years, PT has only recently witnessed a significant uptake in clinical adoption. Secondly, AVO’s approach is new and commercially untested. However, the potential for AVO to build a strong position in the future radiation therapy market is significant and we note that the substantial potential upside derived from revenue sharing agreements are not included in our forecasts at this stage. For our DCF, we forecast AVO’s financial performance for 15 years to 2035E to capture the company’s long-term potential. Free cash flows (“FCF”) are discounted, and risk adjusted using a discount factor of 20%, which we feel is appropriate for a company such as AVO, capturing the commercial risk associated with the company achieving our forecasts. This yields a fair value of £1.35 per share, representing c.3.5x upside to current trading levels. Focus remains on commercial momentum growth and upcoming clinical inflection points While there is a growing case for adoption as evidence of treatments where LIGHT could be of benefit such as LEAP, we maintain the view that developing commercial traction remains the key driver for AVO over the next 12 - 18 months. We expect further news flow regarding system sales in line with upcoming clinical development inflection points including first patient treated, although AVO has not recently updated guidance on when this will occur. The LIGHT system is largely de risked from a technology perspective, in our view. However, despite the project being overseen by a number of world-renowned technical experts, and technology originally developed at CERN, we can appreciate why potential customers may not be willing to take a risk on the capital expenditure at this stage due to a lack of real-world evidence for the system. We therefore see the upcoming clinical development milestones as a key inflection point with the first human application of LIGHT likely to trigger an expansion of AVO’s order book.
daijavu: baner. It won't happen at that price because it would mean the BoD and other major investors selling at an enormous loss. It would cost them all many millions and none of them invested all their money in AVO to give it away at a fraction of what they paid. Especially not when it is on the cusp of making a lot more. The Care Capital/AVO share price was originally nearly 1000p and I would expect some of the founding directors to be looking for a figure more like that just to break even. I doubt if they would voluntarily sell as low as 100p or anything near it. The might play games with us and risk our money but they have been clinging to AVO like grim death. I can't see that changing or them selling out for a pittance when they are on the cusp of realising their dreams. Not unless there is no other way of raising cash and selling out for a pittance and accepting the loss is the only way of getting AVO to market.
Advanced Oncotherapy share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Advanced O..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220119 18:59:49